You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

Avacta announces escalation in clinical study of AVA6000

Avacta – a clinical stage oncology company – has announced that the first-in-human phase 1 trial of AVA6000 Pro-doxorubicin will advance to the third dose cohort. It follows a positive review of safety data from the dosing during the second cohort.